Zoetis Inc. $ZTS Stock Holdings Increased by Advisors Capital Management LLC

Advisors Capital Management LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,837 shares of the company’s stock after buying an additional 7,760 shares during the quarter. Advisors Capital Management LLC’s holdings in Zoetis were worth $22,276,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Burling Wealth Partners LLC boosted its stake in shares of Zoetis by 22.0% during the 2nd quarter. Burling Wealth Partners LLC now owns 27,100 shares of the company’s stock worth $4,226,000 after acquiring an additional 4,880 shares in the last quarter. Hibernia Wealth Partners LLC acquired a new position in shares of Zoetis in the 2nd quarter worth approximately $264,000. Allianz SE increased its position in shares of Zoetis by 30.5% during the 2nd quarter. Allianz SE now owns 2,923 shares of the company’s stock worth $456,000 after purchasing an additional 684 shares in the last quarter. D Orazio & Associates Inc. bought a new stake in Zoetis during the 2nd quarter worth approximately $205,000. Finally, ABN Amro Investment Solutions bought a new stake in Zoetis during the 2nd quarter worth about $4,961,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $121.04 on Friday. Zoetis Inc. has a one year low of $117.26 and a one year high of $181.85. The stock’s 50 day moving average is $141.57 and its 200 day moving average is $151.73. The firm has a market cap of $53.34 billion, a P/E ratio of 20.83, a P/E/G ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the previous year, the firm earned $1.58 earnings per share. The company’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Morgan Stanley reduced their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday. UBS Group dropped their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Argus reissued a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $180.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.